A phase 3 trial of systematic versus response-adapted timed-sequential induction in patients with core binding factor (CBF) acute myeloid leukemia (AML).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Amsacrine; Cytarabine; Daunorubicin; Lenograstim
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 20 Dec 2013 Biomarkers information updated
- 12 Dec 2011 Status changed from recruiting to active, no longer recruiting.
- 03 Oct 2011 Additional associations Assistance Publique Hopitaux de Paris added as reported by ClinicalTrials.gov.